In fact, in RA patients, the treatment with abatacept significantly reduced serum levels of IL-6, IL-12, IL-1β, and soluble E-selectin and ICAM-1, together with the reduction in IFNγ and MMP-1/3 gene expression (Table 1) (102, 103). This evidence concerns the gene IL1B and rheumatoid arthritis.